Connecting labs and industry in new era
When a patient controls a robotic arm with thought alone, the future transforms from science fiction into reality and starts to change work, medicine and industry. Brain-computer interfaces (BCIs), once the realm of neuroscience labs and speculative fiction, are rapidly becoming central to national technology plans. Over the past year China's top-level policy coordination, clinical breakthroughs, industrial investment and venture capital have pushed the field from mere promise to palpable momentum. What was once a lab curiosity is becoming an industrial trajectory, and that makes one question more urgent than any technical hurdle: Do we have the talent to match this moment?
BCIs are by nature interdisciplinary, merging neuroscience, electrical and information engineering, artificial intelligence, biomedical engineering, clinical medicine and materials science. While specialists who master a single domain are essential, industryready BCIs demand a different profile: hybrid professionals who can translate neuroscience into robust hardware, who understand regulatory pathways as well as algorithms, and who know a hospital ward as well as a clean room. In short, the sector needs "boundaryspanners" — people who routinely leap between disciplines and stitch them together.
That need is already reshaping how we think about talent. First, technical fluency alone is not enough. Engineers must learn clinical workflows, ethicists must grasp systems engineering, and clinicians should be fluent in data science. Second, because BCIs sit in a tightly regulated medical space and target global markets, talent must couple an international outlook with regulatory savvy: device registration, clinical trial standards, international norms on ethics and data, and an ability to navigate export and standards regimes.
Meeting that bar means redesigning talent pipelines across three axes: university curricula, industry-academia collaboration, and talent evaluation and incentives.
At the upstream end, higher education must stop operating in disciplinary silos. Universities should offer integrated degree tracks that map a clear progression from undergraduate basics to doctoral depth, with coursework and lab rotations that deliberately blend neuroscience, computing, materials and clinical practice. Long-cycle training from a bachelor program through PhD will produce researchers who can both invent and shepherd inventions toward real products. Some institutions are already experimenting with such models: cross-college platforms that place medical schools, computing departments and engineering faculties in the same curriculum have proven a practical way to grow integrative thinking from day one.
Second, the real proving ground for BCI expertise is industry. We need far deeper industry-university partnerships than the occasional internship or sponsored lab. Flagship platforms — joint research centers, shared testbeds, co-supervised doctoral projects and clinical trial consortia — will allow students and researchers to work on market-facing problems under realistic constraints. Embedding students in product development cycles accelerates their learning curve and produces talent that can immediately tackle commercialization bottlenecks: manufacturability, clinical safety, scalability and post-market surveillance.
Third, talent assessment and incentives must change. Traditional metrics — single-discipline publications, narrow citation counts or short-term product metrics — fail to reward translational, cross-disciplinary work. Evaluation systems should recognize team science, translational milestones, regulatory accomplishments and successful industry collaborations. Funding and promotion rules that favor integrative projects, support early-career researchers in risky translational work, and reward movement between academia and industry will help cultivate a balanced ecosystem.
Beyond domestic capacity building, BCIs are an inherently international field. To claim a role in shaping standards and markets, a country must both attract global talent and internationalize its own. This calls for two complementary strategies. First, targeted international recruitment: attract leading scientists and teams with appealing research conditions, stable career pathways and clear routes for translating discoveries into companies. Second, send domestic talent outward: fund joint PhD programs, multicenter clinical trials and visiting scholar exchanges so local researchers bring back not only expertise but also networks and credibility in global standard-setting bodies.
Throughout all this, ethics and governance cannot be an afterthought. Training must include rigorous coursework on medical ethics, data protection, informed consent and the societal implications of cognitive interfaces. Engineers and clinicians need shared fluency so that safety, privacy and social responsibility are designed into systems from the outset — not bolted on as compliance checkboxes.
BCIs represent more than a new product category. They are a test of whether a nation can reconfigure its talent base to meet a form of technological complexity that defies traditional departmental lines. That reconfiguration requires willpower, imagination and commitment. It also demands humility: assembling the right people will take more than top-down directives; it will require iterative experiments in education, new forms of career mobility and an openness to international collaboration.
The technical bricks for an industrial BCI ecosystem have been laid. The missing mortar is talent shaped for translation and scale. The task now is to pour that mortar by redesigning curricula, deepening industry ties, reforming incentives and internationalizing training. Do it right, and a new generation of hybrid experts will carry BCIs from high-tech demo rooms into everyday clinics, factories and services. Do it poorly, and those demos will remain exceptions rather than the foundations of a new industrial landscape.
The choices are simple: build the people alongside the technology, or watch the technology fall short of its potential.
The author is a member of the 14th National Committee of the Chinese People's Political Consultative Conference and the vice-president of Tianjin University.
The views don't necessarily reflect those of China Daily.
